Who's Who In The IRA Court Drama

Pink Sheet offers a graphical guide to the lawyers behind the briefs and at the podiums for the big showdown in Trenton.

court room
• Source: Shutterstock

See our companion story for coverage of who said what during oral argument.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

PBMs No Longer Profit From Rebates But Plans Benefit; Should Sponsors Push More For Reform?

 
• By 

Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.

340B Not Designed To Pass Savings Directly To Patients, Hospitals Tell Senate Committee

 
• By 

Respondents to a Senate investigation that could re-energize 340B reform efforts said hospitals offer patient assistance programs and use 340B revenue for “capital improvement projects” and “community benefit programs,” though they do not account for specific program revenue allocations.

If CMS Takes Over 340B, Will Government Allow Rebate Model Changes?

 
• By 

Manufacturers have supported the proposed shift in oversight authority, which could create a more pharma-friendly environment in the drug discount program, but uncertainty remains.

Europe Should Pay Drug Prices More In Line With US, Two Pharma CEOs Argue

 
• By 

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

More from Market Access